Addition of bevacizumab to thoracic perfusion for treating malignant pleural effusions-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Addition of bevacizumab to thoracic perfusion for treating malignant pleural effusions

Published:2024-05 Issue:5 Volume:47 Page:2331-2332
ISSN:1015-9584
Container-title:Asian Journal of Surgery
language:en
Short-container-title:Asian Journal of Surgery

Author:

Weng Changfang,Yu Dongling,Meng Zhu,Pan Feng^ORCID

Publisher

Elsevier BV

Reference5 articles.

1. The meta-analysis of bevacizumab combined with platinum-based treatment of malignant pleural effusions by thoracic perfusion;Shen;J Oncol,2022

2. Differential proteome profiling of pleural effusions from lung cancer and benign inflammatory disease patients;Wang;Biochim Biophys Acta,2012

3. Albumin paclitaxel combined with intrapleural infusion of bevacizumab + lobaplatin for the second-line treatment of patients with non-squamous non-small cell lung cancer;Hou;J Oncol,2022

4. Clinical efficacy of bevacizumab combined with cisplatin in the treatment of malignant pleural effusion and ascites caused by lung cancer: a randomized trial;Zhou;Ann Palliat Med,2021

5. Effective treatment for malignant pleural effusion and ascites with combined therapy of bevacizumab and cisplatin;Jiang;Anticancer Res,2016

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP